Oncolytics Biotech (NASDAQ: ONCY) has obtained a new U.S. patent protecting its pelareorep cancer immunotherapy manufacturing process until 2044, strengthening its intellectual property portfolio.

Key Highlights

  • Oncolytics Biotech (NASDAQ: ONCY) secured a U.S. patent covering its pelareorep manufacturing process, extending protection to 2044.
  • A separate method-of-use patent application, if granted, could extend intellectual property rights to 2046.
  • The patent strengthens commercial-scale production capabilities for the investigational cancer immunotherapy.
  • Oncolytics plans additional patent filings in 2026 to expand pelareorep’s intellectual property estate.
  • Pelareorep has FDA Fast Track designation for colorectal and pancreatic cancer treatment.

Oncolytics Biotech (NASDAQ: ONCY) has reinforced its intellectual property position with a new U.S.

patent for its pelareorep cancer immunotherapy.

The patent, issued by the U.S.

Patent and Trademark Office, safeguards the company’s proprietary manufacturing process until 2044.

This development bolsters Oncolytics’ ability to produce pelareorep at commercial scale, a critical step as the therapy advances toward potential regulatory approval.

The patent covers key aspects of pelareorep’s production, ensuring consistency in manufacturing.

If granted, this could extend protection to 2046, further securing the therapy’s long-term commercial viability.

The company plans additional patent filings in 2026 to expand its intellectual property estate across new therapeutic applications and combination treatments.

Pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic, is designed to convert immunologically "cold" tumors into "hot" ones by activating immune responses.

The therapy has shown promise in clinical studies for pancreatic, breast, anal, and colorectal cancers.

Oncolytics is currently advancing pelareorep in combination with chemotherapy and checkpoint inhibitors, particularly in metastatic gastrointestinal cancers where it holds FDA Fast Track designation.

The new patent aligns with Oncolytics’ strategy to build a durable intellectual property portfolio.

The company is also pursuing strategic partnerships to accelerate pelareorep’s path to market.

Investors are closely monitoring pelareorep’s progress, given its potential in high-unmet-need cancer markets.

The extended patent protection reduces competitive risks and enhances Oncolytics’ negotiating position with potential partners.

However, the therapy’s success hinges on clinical trial outcomes and regulatory decisions, which remain key catalysts for the stock.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.